Viral Vectors in Neurotherapeutics

(non-CME activity)

Date/Time: Saturday, October 20, 2018 - 6:00 PM to 9:00 PM
Type: Pre-Meeting Symposium
Area: Neurotherapeutics/Gene Therapy
Room: Centennial II

Session Overview

Chair: Conrad Weihl, MD, PhD – Washington University in St. Louis
Co-Chair: Pedro Gonzalez-Allegra, MD, PhD – University of Pennsylvania

Viral vector-based gene delivery approaches for neurological disorders hold great promise. Just last year the first FDA approved AAV therapy moved into the clinic. However, there are many challenges to gene therapy that must be successfully navigated that include first in human toxicity studies, vector development, manufacturing and regulatory compliance. The goal of this symposium will be to demonstrate the basic science of viral vectors, pre-clinical model development, target identification and ultimately therapeutic trials using a powerful platform of gene-based delivery. These speakers will span industry to academics and a range neurologic disorders from the CNS to the peripheral nervous system.

Objectives

  • Understand AAV based gene delivery.

  • Understand the limitations of gene therapy approaches.

  • Appreciate the complexities of bringing novel therapies to the clinic.